Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 5 | 2017 | 463 | 0.730 |
Why?
|
| Tuberculosis, Pulmonary | 4 | 2017 | 254 | 0.700 |
Why?
|
| Tuberculosis | 4 | 2016 | 573 | 0.680 |
Why?
|
| Sputum | 3 | 2016 | 111 | 0.540 |
Why?
|
| Postpericardiotomy Syndrome | 1 | 2016 | 4 | 0.530 |
Why?
|
| Pleural Effusion | 1 | 2016 | 101 | 0.490 |
Why?
|
| Population Surveillance | 1 | 2016 | 383 | 0.430 |
Why?
|
| Antitubercular Agents | 3 | 2016 | 349 | 0.420 |
Why?
|
| Feces | 1 | 2015 | 708 | 0.400 |
Why?
|
| Asthma | 3 | 2004 | 745 | 0.290 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2016 | 362 | 0.270 |
Why?
|
| Life Support Care | 1 | 2005 | 45 | 0.250 |
Why?
|
| Brain Death | 1 | 2005 | 53 | 0.240 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2005 | 104 | 0.240 |
Why?
|
| Goiter | 1 | 2003 | 7 | 0.220 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2003 | 11 | 0.210 |
Why?
|
| Bronchoscopy | 2 | 2018 | 158 | 0.190 |
Why?
|
| Heart Arrest | 1 | 2005 | 341 | 0.190 |
Why?
|
| Radiography, Thoracic | 2 | 2017 | 156 | 0.180 |
Why?
|
| Clinical Deterioration | 1 | 2020 | 11 | 0.180 |
Why?
|
| Patient Handoff | 1 | 2020 | 26 | 0.180 |
Why?
|
| Pregnancy Complications | 1 | 2004 | 507 | 0.170 |
Why?
|
| Bronchial Neoplasms | 1 | 2018 | 15 | 0.150 |
Why?
|
| Tracheal Neoplasms | 1 | 2018 | 21 | 0.150 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2018 | 61 | 0.150 |
Why?
|
| Leiomyoma | 1 | 2018 | 90 | 0.140 |
Why?
|
| Pulmonary Atelectasis | 1 | 2017 | 14 | 0.140 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2017 | 39 | 0.140 |
Why?
|
| Bacterial Typing Techniques | 1 | 2017 | 103 | 0.140 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2016 | 65 | 0.130 |
Why?
|
| Bacteriological Techniques | 1 | 2015 | 91 | 0.120 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2015 | 23 | 0.120 |
Why?
|
| Rifampin | 1 | 2016 | 146 | 0.120 |
Why?
|
| Catheters, Indwelling | 1 | 2016 | 155 | 0.120 |
Why?
|
| Latent Tuberculosis | 1 | 2016 | 83 | 0.120 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 2024 | 0.120 |
Why?
|
| Weight Gain | 1 | 2016 | 401 | 0.110 |
Why?
|
| Humans | 19 | 2020 | 123122 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 2837 | 0.100 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 730 | 0.090 |
Why?
|
| Aza Compounds | 1 | 2009 | 15 | 0.080 |
Why?
|
| Adult | 8 | 2018 | 29030 | 0.080 |
Why?
|
| Directly Observed Therapy | 1 | 2008 | 24 | 0.080 |
Why?
|
| Isoniazid | 1 | 2009 | 70 | 0.080 |
Why?
|
| Female | 11 | 2018 | 65443 | 0.080 |
Why?
|
| Quinolines | 1 | 2009 | 97 | 0.080 |
Why?
|
| Critical Care | 2 | 2005 | 645 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2008 | 254 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2016 | 12121 | 0.070 |
Why?
|
| Mediastinum | 1 | 2006 | 41 | 0.070 |
Why?
|
| Histoplasmosis | 1 | 2006 | 46 | 0.070 |
Why?
|
| Pregnancy | 3 | 2018 | 7143 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 1873 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 935 | 0.070 |
Why?
|
| Male | 7 | 2016 | 60036 | 0.060 |
Why?
|
| Anti-HIV Agents | 1 | 2008 | 305 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 1308 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 2396 | 0.060 |
Why?
|
| Medication Adherence | 1 | 2008 | 388 | 0.060 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 180 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 1089 | 0.060 |
Why?
|
| Middle Aged | 4 | 2016 | 25971 | 0.060 |
Why?
|
| Safety | 1 | 2004 | 217 | 0.060 |
Why?
|
| Obstetric Labor Complications | 1 | 2004 | 96 | 0.060 |
Why?
|
| Acute Disease | 2 | 2004 | 1090 | 0.050 |
Why?
|
| Fluticasone | 1 | 2003 | 15 | 0.050 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2004 | 107 | 0.050 |
Why?
|
| Androstadienes | 1 | 2003 | 49 | 0.050 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 1 | 2002 | 8 | 0.050 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2002 | 35 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2003 | 194 | 0.050 |
Why?
|
| Thyroidectomy | 1 | 2003 | 102 | 0.050 |
Why?
|
| Vasculitis | 1 | 2002 | 49 | 0.050 |
Why?
|
| Glomerulonephritis | 1 | 2002 | 73 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2005 | 597 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2004 | 452 | 0.050 |
Why?
|
| Young Adult | 1 | 2015 | 8864 | 0.050 |
Why?
|
| Risk Factors | 1 | 2016 | 10017 | 0.050 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2005 | 313 | 0.050 |
Why?
|
| HIV Infections | 2 | 2008 | 1866 | 0.050 |
Why?
|
| Aged | 2 | 2016 | 19072 | 0.050 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2002 | 147 | 0.050 |
Why?
|
| Hospitals, County | 1 | 2020 | 23 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2003 | 378 | 0.040 |
Why?
|
| Hospital Rapid Response Team | 1 | 2020 | 35 | 0.040 |
Why?
|
| Internal Medicine | 1 | 2020 | 146 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 5047 | 0.040 |
Why?
|
| Heart Rate, Fetal | 1 | 2018 | 62 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2017 | 358 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 1998 | 263 | 0.030 |
Why?
|
| South Africa | 1 | 2016 | 100 | 0.030 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2016 | 35 | 0.030 |
Why?
|
| Brazil | 1 | 2016 | 121 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 239 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1010 | 0.030 |
Why?
|
| Pneumocystis | 1 | 1995 | 11 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 2044 | 0.030 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1995 | 37 | 0.030 |
Why?
|
| Texas | 2 | 2020 | 3546 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1995 | 159 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1995 | 462 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2016 | 481 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2020 | 16003 | 0.030 |
Why?
|
| Prevalence | 2 | 2016 | 2407 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2020 | 4704 | 0.020 |
Why?
|
| Recurrence | 1 | 2015 | 1422 | 0.020 |
Why?
|
| United States | 2 | 2016 | 10626 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2020 | 1158 | 0.020 |
Why?
|
| Fluoroquinolones | 1 | 2009 | 99 | 0.020 |
Why?
|
| Histoplasma | 1 | 2006 | 28 | 0.020 |
Why?
|
| Arm | 1 | 2006 | 76 | 0.020 |
Why?
|
| Edema | 1 | 2006 | 134 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 1681 | 0.020 |
Why?
|
| Fibrosis | 1 | 2006 | 429 | 0.010 |
Why?
|
| Antifungal Agents | 1 | 2006 | 293 | 0.010 |
Why?
|
| Pain | 1 | 2006 | 470 | 0.010 |
Why?
|
| Causality | 1 | 2002 | 83 | 0.010 |
Why?
|
| Mutation | 1 | 2016 | 5771 | 0.010 |
Why?
|
| Coronaviridae | 1 | 1998 | 4 | 0.010 |
Why?
|
| Urban Health | 1 | 1998 | 73 | 0.010 |
Why?
|
| Rhinovirus | 1 | 1998 | 59 | 0.010 |
Why?
|
| Orthomyxoviridae | 1 | 1998 | 50 | 0.010 |
Why?
|
| DNA Primers | 1 | 1998 | 660 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1998 | 477 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1998 | 1291 | 0.010 |
Why?
|
| Tissue Fixation | 1 | 1995 | 35 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1998 | 1311 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1995 | 183 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1998 | 1134 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 1998 | 3379 | 0.010 |
Why?
|